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AdolescenceAlthough sex steroids are known to modulate brain dopamine, it is still unclear how testosterone modiﬁes loco-
motor behaviour controlled, at least in part, by striatal dopamine in adolescent males. Our previous work sug-
gests that increasing testosterone during adolescence may bias midbrain neurons to synthesise more
dopamine.We hypothesised that baseline and amphetamine-induced locomotionwould differ in adultmales de-
pending on testosterone exposure during adolescence. We hypothesised that concomitant stimulation of estro-
gen receptor signaling, through a selective estrogen receptor modulator (SERM), raloxifene, can counter
testosterone effects on locomotion.
Male Sprague-Dawley rats at postnatal day 45 were gonadectomised (G) or sham-operated (S) prior to the typ-
ical adolescent testosterone increase. Gonadectomised rats were either given testosterone replacement (T) or
blank implants (B) for six weeks and sham-operated (i.e. intact or endogenous testosterone group) were given
blank implants. Subgroups of sham-operated, gonadectomised and gonadectomised/testosterone-replaced rats
were treated with raloxifene (R, 5 mg/kg) or vehicle (V), daily for the ﬁnal four weeks. There were six groups
(SBV, GBV, GTV, SBR, GBR, GTR). Saline and amphetamine-induced (1.25 mg/kg) locomotion in the open ﬁeld
was measured at PND85.
Gonadectomy increased amphetamine-induced locomotion compared to rats with endogenous or with exoge-
nous testosterone. Raloxifene increased amphetamine-induced locomotion in rats with either endogenous or ex-
ogenous testosterone. Amphetamine-induced locomotion was negatively correlated with testosterone and this
relationship was abolished by raloxifene.
Lack of testosterone during adolescence potentiates and testosterone exposure during adolescence attenuates
amphetamine-induced locomotion. Treatment with raloxifene appears to potentiate amphetamine-induced lo-
comotion and to have an opposite effect to that of testosterone in male rats.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Circulating androgens and estrogens, produced mainly by the go-
nads, cross the blood brain barrier and directly modulate brain func-
tion in regions with cells expressing androgen (AR) and estrogen
(ER) receptors. While many neuronal types express sex steroid re-
ceptors, we are particularly interested in sex-steroid responsiveness
of midbrain dopamine neurons, which are known to express AR andoratory, Neuroscience Research
ax: +61 2 9399 1005.
rves-Tyson).
c. This is an open access article underERs (Creutz and Kritzer, 2004; Kritzer and Creutz, 2008; Perez et al.,
2003; Purves-Tyson et al., 2012; Ravizza et al., 2002; Shughrue et al.,
1997). Dopamine-related brain functions are varied and includemodal-
ities such as movement, reward, pleasure, motivation, compulsion and
perseveration, attention and working memory and inﬂuence decision
making, addiction and psychosis (Arnsten, 2013; Brisch et al., 2014;
Leyton and Vezina, 2014). Male adolescence is a period of increasing
exposure to circulating testosterone, as well as a period of higher inci-
dence of risk taking behavior and onset of schizophrenia, both of
which are characterized by changes in dopamine (Christie et al., 1988;
Leyton and Vezina, 2014; Markham, 2012). Previously, we found that
male castration prior to adolescence can lead to altered socialthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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primates (Morris et al., 2010; Richards et al., 2009). It is, however,
unclear if and how developmental changes in testosterone may con-
tribute to the regulation of other more commonly studied dopamine-
dependent behaviors in rodents. Therefore, a focus of this study was
to examine the effect of testosterone during male adolescence on a
pharmacologically-induced behavior related to dopamine neuro-
transmission, i.e amphetamine-induced locomotion, in adulthood.
We recently under took a molecular examination as to how testos-
terone over adolescence may modulate dopamine parameters in the
nigrostriatal pathway in male rats. We reported that increasing testos-
terone over the male adolescent period (postnatal day [PND] 45-60)
resulted in an increase in dopamine synthesis potential (tyrosine hy-
droxylase [TH] protein expression) in the young adult substantia nigra
(Purves-Tyson et al., 2012) but not in the striatum (Purves-Tyson
et al., 2014), but also found in late adolescent rhesus macaques that cir-
culating testosterone levels correlated positively with TH levels in the
putamen (Morris et al., 2010). We also reported, in young adult rats,
that increasing testosterone over the adolescent period increased dopa-
mine receptor D2 (DRD2) gene expression in both the substantia nigra
and dorsal striatum (Purves-Tyson et al., 2014). Further, gene expres-
sion of enzymes involved in dopamine transport and metabolism
were also increased by adolescent testosterone in the young adult
nigrostriatal pathway (Purves-Tyson et al., 2012, 2014). However,
young adult striatal dopamine levels were not changed by adolescent
testosterone; rather, striatal dopamine turnover (ameasure of dopami-
nergic activity)was increased upon testosterone removal, and this stim-
ulatory effect was attenuated by testosterone replacement (Purves-
Tyson et al., 2014). From thesemolecular and biochemical observations,
it is unclear whether the apparent increase in dopamine synthesis ca-
pacity in the substantia nigra and the modulation of other dopamine
pathway molecules in the substantia nigra and striatum as a result of
changed testosterone during adolescence contributes to an increase,
or a decrease, of overall dopamine tone or in dopamine-related behav-
iors in adulthood.
In rodents, a well-described behavioral response to amphetamine, is
an increase in locomotion. This hyperlocomotive response may be due
to changes in multiple neurotransmitter systems as amphetamine
increases monoamine release and inhibits reuptake by reversing the di-
rection of the transporters (Jones et al., 1998; Sulzer et al., 1995, 2005).
In particular, the increase in dopamine concentration in the synapse in-
duced by amphetamine, has been linked to the locomotor-enhancing
effects of amphetamine as they are attenuated bydopamineD2 receptor
blockade (Lapin andRogawski, 1995; O'Neill and Shaw, 1999). Although
other neurotransmitter systems (e.g. other catecholamines, serotonin,
glutamate) can also contribute, either directly or indirectly, to the
amphetamine-induced locomotor response (Sulzer et al., 2005), in
this study we have emphasized the contribution of dopamine due to
our molecular measures relating to the modulation of dopamine func-
tion by testosterone, althoughwe have notmeasured dopamine directly
(Purves-Tyson et al., 2012, 2014).
Although sex steroid effects on different aspects of dopamine ac-
tivity have received much attention [reviewed in (Sanchez et al.,
2010)], the role of androgens in modulating dopamine pathways in
males, particularly during adolescence, is not fully understood. As
sex hormones exert unique organizational effects on brain and
evolving behavior during adolescence, it is important to study this
developmental period. Preclinical studies in mostly adult male rats
report that testosterone can both increase (de Souza Silva et al., 2009;
Thiblin et al., 1999) and decrease (Beatty et al., 1982; Dluzen and
Ramirez, 1989; Forgie and Stewart, 1994; Menniti and Baum, 1981)
striatal dopamine activity. Testosterone treatment increased dopamine
turnover but not dopamine synthesis in the striatum of adult male rats
(Thiblin et al., 1999) and acute intranasal testosterone treatment of
adult male rats increased dopamine in the striatum (de Souza Silva
et al., 2009). Other studies have shown that testosterone removal bycastration of adult male rats increased spontaneous locomotion
(Dluzen and Ramirez, 1989) and increased the locomotor response to
amphetamine (Beatty et al., 1982; Forgie and Stewart, 1994) and that
both effects were reversed by exogenous testosterone replacement. A
further study in male rats, investigating sex steroid modulation during
adolescence, reported that gonadectomy and testosterone replacement
immediately prior to adolescence reduced amphetamine-induced loco-
motion compared to non-testosterone replaced gonadectomised in
adulthood (Menniti and Baum, 1981). In this study, we also have inves-
tigated amphetamine-induced locomotion in adulthood after circulat-
ing testosterone was altered during adolescence.
There is evidence that estrogen treatment of adult male rats mod-
ulates aspects of the dopamine pathway in the striatum that may
contribute to reduced dopamine neurotransmission, e.g. estrogen
decreased DRD2 mRNA levels in the striatum (Lammers et al., 1999).
The selective estrogen receptor modulator, raloxifene, can act as an ER
agonist in the brain, as seen in the hippocampus where both raloxifene
and estrogen administration restore choline acetyltransferase activity
in ovariectomised female rats (Wuet al., 1999). Themany studies inves-
tigating estrogen effects on dopamine pathways [reviewed in (Sanchez
et al., 2010)] indicate that estrogen receptor-mediated effects can
both decrease and increase different measures of dopamine neuro-
transmission, and since molecular alterations in dopamine-related
pathways in male rats appeared to be mediated by AR signaling
(Purves-Tyson et al., 2014), we tested if concomitant stimulation of
ER signaling through raloxifene may be able to modify testosterone
effects on locomotion. In this study, we therefore also tested the
extent to which raloxifene treatment in young adulthood (after tes-
tosterone modulation during adolescence) impacts amphetamine-
induced locomotive behavior both in the absence of testosterone
(i.e. gonadectomised) and in the presence of endogenous (sham-
operated) or exogenous testosterone (i.e. gonadectomy with testos-
terone replacement by subdermal silastic implant) in adult male rats.
Materials and methods
Animals
All animal experiments were approved by the Animal Care and
Ethics Committee of the University of New SouthWales (Ethics number
ACEC 13/5A) in accordance with the National Health and Medical Re-
search Council of Australia’s Code of Practice for the Care and Use of An-
imals for Experimental Purposes. Male Sprague-Dawley rats were used
for all experiments (Animal Resource Centre, Perth,WA, Australia). Rats
were received at PND31 or 32 and group housed (3–4/cage) in 12/12 h
light/dark phases with constant humidity and temperature and free ac-
cess to water and standard rat chow.
Gonadectomy, testosterone replacement and raloxifene treatment
Surgical procedure
For surgery and hormone replacement, ratswere anaesthetisedwith
an isoﬂuorane vaporisor set at 5% to induce anaesthesia and then set at
3% for maintenance of anaesthesia. Rats were gonadectomised via a
midline abdominal incision and bilateral removal of the testes after
ligating the vas deferens and associated blood vessels. Sham-
operated animals underwent abdominal surgery but gonads were
left in place. Silastic implants were placed subdermally between
the shoulder blades at time of gonadectomy with a small incision
closed with 1–2 silk sutures. Implants were 1 cm long, internal diam-
eter 1.47mm, outer diameter 1.95mm and ﬁlled with crystalline ste-
roid (ends sealed with silastic adhesive). At experiment end the
presence of the silastic implants was conﬁrmed. The testosterone
implants have been characterized in previous studies and achieve
physiological or supra-physiological, steady-state serum testoster-
one levels and maintain seminal vesicle weights comparable to that
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et al., 1995). Body weight measurements were taken weekly
throughout the experiment.
Treatments groups
Male Sprague-Dawley rats experience a gradual increase in circu-
lating testosterone between 45 and 60 days of age (Saksena and Lau,
1979; Walker et al., 2012) and at ~60 days of age are considered
young adults and by ~90 days of age are considered adults. Male
rats were gonadectomised (G) or sham operated (S) at 45 days of
age (prior to the adolescent testosterone increase) and given contin-
uous replacement testosterone (T) in the form of testosterone ﬁlled
or empty silastic implants (Blanks, B) for six weeks. Two weeks fol-
lowing gonadectomy or sham operations daily subcutaneous injections
of raloxifene (R, 5 mg/kg) or vehicle (V, 5% dimethylsulphoxide, 47.5%
monopropyleneglycol and 47.5% normal saline [0.9% NaCl]) were
started and continued daily for four weeks with testosterone or blank
implants remaining in place. This dose of raloxifene (5 mg/kg) was se-
lected as it fully restores hippocampal choline acetyltransferase activity
in ovariectomised rats in amanner similar to estrogen (Wuet al., 1999).
All together, there were six groups of rats (n = 6-11 rats/group): 1.
sham-operated with empty (blank) implant and vehicle injections
(SBV); 2. gonadectomy with empty implant and vehicle injections
(GBV); 3. gonadectomy with testosterone implant and vehicle injec-
tions (GTV); 4. shamoperatedwith empty implant and raloxifene injec-
tions (SBR); 5. gonadectomy with empty implant and raloxifene
injections (GBR); and 6. gonadectomy with testosterone implant and
raloxifene injections (GTR).
Amphetamine-induced locomotor activity
Locomotor activity tests (PND85 i.e. 39 days post surgery) were con-
ducted in four open ﬁeld apparatus (65×65×65 cm, Tru Scan Activity
System, Coulbourn Instruments, USA). Movement in each arena was
measured by infrared beams. Horizontal activity was the main measure
of locomotion.
Locomotion tests were always commenced between 9:30 and
10:00 am to ensure sham-operated rats were in a similar phase in
their testosterone circadian rhythm. On day of locomotion testing,
rats were placed in the test arenas and locomotor activity measured
during a 30 minute habituation period. Animals were then brieﬂy
removed from the apparatus and received a vehicle injection (iso-
tonic 0.9% saline solution) and returned to the same apparatus and
locomotion measured for a further 30 minutes of testing (consid-
ered as “saline baseline” activity). The animals were then removed
from the apparatus a second time and received an amphetamine in-
jection (1.25 mg/kg, intraperitoneally, National Measurement Insti-
tute, Sydney, Australia). They were immediately returned to the
same arena and locomotion response to amphetamine (amphet-
amine-induced locomotion) was monitored for a further 2 hours.
This low dose of amphetamine was selected as it is within the stan-
dard dose range (0.2–2.0 mg/kg) used in adult male rats to induce
increased locomotion but not stereotypy, which occurs at higher
doses (5–10 mg/kg) (Randrup and Munkvad, 1974; Sharp et al.,
1987) and, in our hands, produced locomotor effects comparable
to previously published data using a similar saline/amphetamine in-
jection paradigm in adult male Sprague-Dawley rats (Byrne et al.,
2013). Locomotion data was analyzed over the entire 180 minute test-
ing period.
Seminal vesicle measurements, serum collection and sex steroid
measurements
At experiment end (PND88, three days after behavioural assess-
ment) animals were sacriﬁced by isoﬂuorane aneasthesia and decap-
itation. Trunk blood was collected in serum tubes, left at roomtemperature for approximately 1 h and centrifuged at 12000 rpm
at 4 °C for 18 min. Serum was stored at −80 °C until required for
sex steroid measurements. Seminal vesicles were removed and
weight of each seminal vesicle recorded. The average weight of the
two seminal vesicles for each rat was then determined and this
value used to determine group means.
Sex steroids were quantiﬁed in serum using stable isotope dilu-
tion liquid chromatography-tandemmass spectroscopy as described
(Harwood and Handelsman, 2009) and adapted for rodents
(McNamara et al., 2010). The limit of detection for testosterone is
0.01 ng/ml. In thirteen out of fourteen gonadectomised rats without
testosterone replacement (GBV and GBR groups), testosterone was
not detectable and to allow for statistical comparisons a value of
0.01 ng/ml was assigned to those samples.
Statistical analysis
Statistical analyses were conducted using SPSS software (IBM SPSS
Statistics, version 10) or GraphPad Prism (Graphpad Software, version
6) and p b or = 0.05 was considered statistically signiﬁcant. Data are
shown as mean ± standard error of the mean (SEM). Seminal vesicle
weight (g) and testosterone levels (ng/ml) were compared using one-
way ANOVA with ‘treatment’ as the independent variable with Fisher’s
least signiﬁcant differences (LSDs) post hoc analysis. Body weight over
the duration of the experiment was analysed with two-way repeated
measures ANOVA with a Greenhouse-Geisser correction with ‘treat-
ment’ as the between subjects factor and ‘time’ as the within subjects
factor. Signiﬁcant main effect of treatment was followed up with
Tukey’s post hoc analysis and a signiﬁcant interaction between time
and treatment was followed up with Sidak’s pairwise comparisons.
Locomotion data is presented as distancemoved (cm) in 5min time
bins over the full 180 min period (as per (Byrne et al., 2013)). A single
rat in each of the GTR, SBV and SBR groups was removed from the
study as their activity did not increase in response to amphetamine rel-
ative to baseline activity andwere therefore deﬁned as non-responders.
Outliers (n = 3) were removed by analysing total distance moved (i.e.
area under the curve) after amphetamine injection by Grubbs test for
outliers (GraphPad Software, online calculators). Two outliers were re-
moved from the SBV group and one outlier from the GBR group.
The distance moved in the open ﬁeld arena in 5 min time bins
over the 180 min period was analysed with two-way repeated mea-
sures ANOVA with a Greenhouse-Geisser correction with ‘treatment’
as the between subjects factor and ‘time’ as the within subjects fac-
tor. Signiﬁcant main effect of treatment was followed up with
Tukey’s post hoc analysis and a signiﬁcant interaction between time
and treatment was followed up with Sidak’s pairwise comparisons.
All six test groups were analysed together and all 6 line graphs are
shown in Fig. 3A. However, for ease of viewing the data, the compar-
isons between groups are presented on different graphs with some
groups represented on more than one graph (Figs. 4, 5, 6). In all
cases, data are presented as mean ± standard error of the mean
(SEM) and p b 0.05 was considered statistically signiﬁcant. The
total distance moved after amphetamine injection was analyzed
with one-way ANOVA with treatment as the independent variable
followed by Fisher’s LSDs (Fig. 3D).
To test for signiﬁcant differences in distance travelled in both the
habituation period and the saline baseline period, the total distance
moved during each of these 30 min periods was compared using
one-way ANOVAwith treatment as the independent variable follow-
ed by Fisher’s LSDs.
Eta squared (η2) is reported when analysis was by ANOVA and
Cohen’s d is reported for pair-wise comparisons (0.2 is a small effect
size, 0.5 is amodest effect size and N0.8 is a large effect size). Eta squared
was calculated manually (Field, 2005) and Cohen’s d was calculated
using Ellis, P.D. (2009), "Effect size calculators," website. www.polyu.
edu.kh/mm/effectsizefaqs/calculators/calculators.html.
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amphetamine-induced locomotion, the 2 hour period following am-
phetamine was also divided into four 30 min time periods and
Pearson’s correlations were performed in groups with testosterone
(SBV, GTV) and total distance moved during all six 30 min time pe-
riods. To determine how this relationship was changed by raloxifene
treatment, Pearson’s correlations were then performed in groups
with both testosterone and raloxifene treatment (SBR with endoge-
nous testosterone, GTR with replaced testosterone) and total dis-
tance moved during each 30 minute time period.
Results
Conﬁrmation of sex steroid replacement by serum measurements and
organ weight
As expected, there was a signiﬁcant effect of treatment group when
examining seminal vesicle weights [F (5,45) = 78.4, p b 0.0001, η2 =
0.89] (Fig. 1A). Gonadectomy reduced seminal vesicle weight when
compared to sham operated animals (SBV) in both the GBV (SBV vs.
GBV, p b 0.0001, d = 8.6) and the GBR (SBV vs. GBR, p b 0.0001, d =
8.6) groups and therewere no differences between the gonadectomised
groups as a result of raloxifene treatment (GBV vs. GBR, p=0.97). Sem-
inal vesicles were partly restored to 76% and 88% of the sham group
(SBV) by testosterone replacement in the vehicle and raloxifene (SBV
vs. GTV p b 0.002, d= 1.4 and SBV vs. GTR p= 0.08, d= 0.7) groups,
respectively. There were no differences in seminal vesicle weight be-
tween the groups with gonadectomy and testosterone replacement
with and without raloxifene (GTV vs. GTR, p N 0.05). Raloxifene treat-
ment of intact rats signiﬁcantly reduced seminal vesicle weight (SBV
vs. SBR, p b 0.0001, d= 1.8).
Similarly, there was a signiﬁcant effect of treatment group when ex-
amining circulating testosterone levels measured six weeks after re-
placement [F (5,33) = 16.56, p b 0.0001, η2 = 0.7] (Fig. 1B). In intact
animals, circulating testosteronewas 2.15±0.32 ng/ml and thiswas re-
duced to 0.01 ± 0.0 ng/ml by gonadectomy (SBV vs. GBV, p b 0.0001,
d=3.4). Testosterone implants restored circulating testosterone levels
in the GTV (0.98±0.23 ng/ml) and the GTR (0.77±0.19 ng/ml) groups
(GBVvs. GTV andGBVvs. GTR, both p b 0.05, d=2.7 and 2.3, respective-
ly). Raloxifene treatment signiﬁcantly reduced endogenous testoster-
one levels by 41% from 2.15 ± 0.32 ng/ml in the SBV group to 1.27 ±
0.25 ng/ml in the SBR group (SBV vs. SBR, p=0.005, d=1.2). This effect
of raloxifene on circulating testosterone was maintained in a larger co-
hort of rats (10-14 per group, data not shown).
Over the six week experiment, there was a trend for a main effect of
treatment on body weight [F (5,25) = 2.3, p b 0.072, η2 = 0.32], aB
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tosterone was signiﬁcantly reduced by raloxifene treatment (SBV vs, SBR) in the behavioural csigniﬁcant main effect of time on body weight [F (6,150) = 1116.4,
p b 0.0001, η2 = 0.94] and a signiﬁcant interaction between time and
treatment on body weight [F (30, 150) = 8.9, p b 0.0001] (Fig. 2). At
days 35 and 42 post gonadectomy therewas a reduction in bodyweight
of gonadectomised rats compared to sham-operated rats at both time
points (SBV vs. GBV, p b 0.05, d= 1.5 for both) and this was prevented
by testosterone replacement (SBV vs. GTV, p N 0.05) (Fig. 2). Therewas a
signiﬁcant reduction in body weight due to raloxifene treatment of
sham-operated rats at 35 and 42 days post gonadectomy (SBV vs. SBR,
p b 0.001, d= 2.3 and 2.8, respectively) (Fig. 2). Testosterone replace-
ment prevented the trend for a lack of weight gain experienced by
gonadectomised rats treated with raloxifene [GBV vs. GBR, p= 0.079,
d = 1.6 at 42 days post gonadectomy, GBR vs GTR, p b 0.05 at 35
(d= 1.1) and 42 (d= 1.3) days post gonadectomy] (Fig. 2).
Modulation of baseline and amphetamine-induced locomotion by
testosterone and raloxifene
Locomotion (distance travelled) was assessed over a 180 minute
testing period, which included 30 minutes of habituation in the open
ﬁeld chamber and 30 minutes in the chamber following a saline injec-
tion (saline baseline) prior to a further 120 minutes following an am-
phetamine injection. When distance travelled was analyzed by two-
way repeated measures ANOVA over the 180 minute test period there
was a signiﬁcant main effect of treatment [F (5,37) = 7.7, p b 0.0001,
η2 = 0.51] as well as a signiﬁcant main effect of time [F (35,1295) =
80.3, p b 0.0001, η2 = 0.62] and a signiﬁcant interaction between time
and treatment [F (175, 1295)=2.3, p b 0.0001] (Fig. 3A). Refer to online
version for colour ﬁgures.
Locomotion differed between groups during the habituation and the saline
baseline periods
There were signiﬁcant differences in locomotor activity between
groups during the habituation and saline injection periods. To explore
this further, the total distancemoved for each animal in each treatment
group in the habituation and the saline baseline 30 minute periods was
assessed separately by one-wayANOVA. Therewas a signiﬁcant effect of
treatment during the habituation period [F(5,40) = 2.6, p = 0.038,
η2 = 0.34] (Fig. 3B). During the habituation period, there was a trend
for gonadectomised rats to be more active in the novel environment
than the intact rats (GBV vs. SBV, p= 0.056, d= 1.1). Similarly, the in-
tact rats treated with raloxifene (SBR) and the gonadectomised rats
treated with raloxifene only (GBR) moved more than gonadectomised
rats with both testosterone replacement and raloxifene (SBR vs. GTR,
p= 0.023, d= 1.0; GBR vs. GTR, p= 0.012, d= 1.5) (Fig. 3B).SBV GBV GTV SBR GBR GTR
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77T.D. Purves-Tyson et al. / Hormones and Behavior 70 (2015) 73–84Therewas also a signiﬁcant effect of treatment on locomotor activity
during the saline baseline period [F(5,38)= 6.1, p=0.0003, η2= 0.45]
(Fig. 3C). In the 30minutes following saline injection (i.e. saline baseline
period), testosterone removal by gonadectomy (GBV) increased the dis-
tance travelled compared to the intact rats (GBV vs. SBV, p=0.048, d=
0.9) and this was attenuated by testosterone replacement (GBV vs. GTV,
p= 0.009, d= 1.5) (Fig. 3C). Locomotion of intact rats was not altered
by raloxifene treatment during the saline baseline period (SBV vs. SBR,
p N 0.05). However, in gonadectomised rats there was a trend for ralox-
ifene treatment to increase locomotion at saline baseline (GBV vs. GBR,
p=0.068, d=0.8) and this effect was attenuated by testosterone (GBR
vs. GTR, p b 0.0001, d= 2.5) (Fig. 3C).Testosterone attenuated amphetamine-induced hyperlocomotion
The total distance moved (in 120 minutes) for each animal in each
treatment group following amphetamine injection was also assessed
by one-way ANOVA. There was a signiﬁcant effect of treatment follow-
ing amphetamine injection [F(5,33) = 5.1, p = 0.0014, η2 = 0.44]
(Fig. 3D). Therewas a signiﬁcant increase in distance traveledwhen tes-
tosterone was removed (SBV vs. GBV, p b 0.05, Cohen’s d = 1.2 ) and
this was prevented by testosterone replacement (SBV vs. GTV,
p N 0.05; GBV vs. GTV, p b 0.05, Cohen’s d = 1.1). Intact rats treated
with raloxifene travelled further than intact rats without raloxifene
(SBV vs. SBR, p b 0.05, Cohen’s d = 1.3) as did gonadectomised rats
treated with raloxifene compared to gonadectomised rats without ral-
oxifene (GBV vs. GBR, p b 0.05, Cohen’s d = 1.1). There was a trend
for gonadectomised rats treated with raloxifene to travel further than
both the intact rats with raloxifene and the gonadectomised rats with
replacement testosterone (SBR vs. GBR, p b 0.1, Cohen’s d = 0.9; GBR
vs. GTR, p b 0.05, Cohen’s d= 1.1).
The locomotion datawas also analysedwith two-way repeatedmea-
sures ANOVA (as reported above, see Fig. 3A). Removal of circulating
testosterone during adolescence by gonadectomy potentiated the
hyperlocomotion response induced by amphetamine (Fig. 4). Within
30 minutes of amphetamine injection, gonadectomised rats (GBV)
without testosterone showed a greater distance travelled above the
other two groups. The 5 minute pairwise comparisons with p values
and Cohen’s d are shown in Fig. 4. Post hoc comparisons between the
SBV and GBV groups are presented below the SBV group, and the post
hoc comparisons between the GBV and GTV groups are shown above
the GBV group in Fig. 4. There were no statistically signiﬁcant differ-
ences in distance travelled in 5 minute time bins between sham-
operated rats with endogenous testosterone or gonadectomised rats
with testosterone replacement (SBV vs. GTV) (Fig. 4).Raloxifene potentiated amphetamine-induced hyperlocomotion in the
presence of endogenous testosterone
Four weeks of raloxifene treatment of sham-operated male rats
(i.e. with endogenous testosterone, SBV) potentiated amphetamine-
induced locomotion (SBV vs. SBR) bymaintaining increased locomotion
for a longer time (Fig. 5). The distance travelled by intact rats (SBV) and
intact rats treated with raloxifene (SBR) increased at the same rate
following amphetamine injection (Fig. 5, SBV vs. SBR; p N 0.05 for
5 minute time bins between 60 minutes and 115 minute). The dis-
tance travelled by the SBV group began to decline 45 minutes after am-
phetamine injection (i.e. at 105minutes) whereas the distance travelled
by the intact group with raloxifene (SBR) continued to increase until
60 minutes after amphetamine injection (i.e. 115 minutes) when dis-
tance travelled also started to decline towards baseline, but remained
signiﬁcantly higher than the intact rats without raloxifene (Fig. 5,
SBV vs. SBR between 135 minutes and 165 minutes p was between
b0.05 and b0.001 for many 5 minute time bins). The 5 minute
pairwise comparisons with p values and Cohen’s d are shown in
Fig. 5Raloxifene potentiated amphetamine-induced hyperlocomotion in rats
without testosterone
The groupwith the greatest distance travelled in total in response to
amphetamine injectionwas the gonadectomised rats without testoster-
one replacement but treated with raloxifene (GBR) (Figs. 3A and 6).
When gonadectomised rats with testosterone replacement were treat-
ed with raloxifene (GTR) they appeared to start returning toward
lower baseline levels of locomotion slightly before the group without
testosterone replacement (GBR). When comparing distance travelled
in 5 minute time bins there was a trend for the distance travelled by
the GTR group to be less than the GBR group at 170 minutes (p b 0.1,
Cohen’s d=1.6) and thedistance travelled by theGTR groupwas signif-
icantly less at 175 minutes (p b 0.01, Cohen’s d= 1.6) compared to the
GBR group.
However, raloxifene treatment signiﬁcantly increased the
dopamine-potentiating effect of amphetamine on locomotion in
gonadectomised rats with testosterone replacement (GTR) as com-
pared to gonadectomised rats with testosterone without raloxifene
(GTV) (p = 0.02, Cohen’s d = 1.6) and when comparing distance
travelled in 5 minute time bins, this was evident from 15 minutes
following the amphetamine injection (i.e. 95 minutes) when the dis-
tance travelled by the GTV group peaked and started to decline to-
ward baseline and the GTR group continued to increase the
distance travelled until 110 minutes. The 5 minute pairwise
78 T.D. Purves-Tyson et al. / Hormones and Behavior 70 (2015) 73–84comparisons with p values and Cohen’s d are shown in Fig. 6 and in
ﬁgure legend.
Testosterone was negatively correlated with the amount of amphetamine-
induced locomotion
Pearson’s correlations revealed an inverse relationship between lo-
comotion after amphetamine injection and circulating testosteroneA. Locomotor activity over 180 minutes
B. Distance moved in the 30 min habituation period
C. Distance moved in the 30 min saline period
D. Distance moved in the 120 min amphetamine periodlevel at time of sacriﬁce (i.e. 3 days after behavioral testing), when
analysing the groups with either endogenous or exogenous testoster-
one but no raloxifene treatment (SBV, GTV) (Fig. 7). The distance
moved after amphetamine injection was divided into 30 minute time
blocks and the relationship between the total distance moved in each
of the two 30 min time blocks prior to amphetamine injection and
each of the four 30 minute time blocks after amphetamine injection
and terminal circulating testosterone levels was determined with
Pearson’s correlations. There were no signiﬁcant correlations between
distance moved and testosterone levels during the habituation period
(0-30 minutes, r = -0.35, p= 0.27) or the saline baseline period (30-
60 minutes, r = 0.02, p=0.95). However, after amphetamine injection
there was a negative correlation between serum testosterone and dis-
tance travelled in each of the last two 30 minute time bins
(SBV + GTV; 120-150 minutes, r = -0.70, p= 0.012 and 150-180 mi-
nutes, r = -0.76, p= 0.004) (Fig. 7). This indicates that the higher the
terminal serum testosterone concentration, the less amphetamine-
induced locomotion. These negative correlations were not found when
levels of testosterone and levels of activity were examined in rats treat-
ed with raloxifene (SBR + GTR; 120-150 minutes, r = 0.37, p = 0.30
and 150-180 minutes, r = 0.34, p= 0.33) (Fig. 7).
Discussion
Summary of ﬁndings
We report that testosterone removal prior to adolescence in-
creases the adult locomotive response, while both endogenous and
exogenous testosterone exposure during adolescence decrease the
adult locomotive response, following administration of amphet-
amine. We report that raloxifene treatment increases the locomotion
response to amphetamine in intact ratswith circulating testosterone.We
also show that in gonadectomised rats without circulating testosterone,
raloxifene increases the locomotor response to amphetamine and in
gonadectomised rats with exogenous testosterone, raloxifene largely
overrides the attenuating effect of testosterone on amphetamine-
induced locomotion. Further, we show a negative correlation between
circulating testosterone levels and degree of amphetamine-induced
hyperlocomotion, and we ﬁnd that this relationship is lost when rats
are treated with raloxifene. This demonstrates that not only can raloxi-
fene potentiate amphetamine-induced locomotion alone, but at the sin-
gle concentration used in this study, it appears to largely override any
locomotor blunting changes related to testosterone levels.
Baseline locomotion differs between treatment groups
The increased locomotion in response to a saline injection in
gonadectomised rats compared to gonadectomised rats with testoster-
one replacement or sham-operated rats could be due to many different
effects. In our previous study, we reported an increase in baseline dopa-
mine turnover, a measure of dopamine activity, in the dorsal striatum
following two weeks of gonadectomy compared to intact rats and thisFig. 3. The effect of gonadectomy and testosterone replacement on amphetamine-induced
locomotion during the habituation and saline baseline periods. A. Distance traveled over
the 3 h observation period in 5 minute time bins showing the 30 min habituation period
starting at time 0 min when animals were placed in the chamber and time 30 min when
saline injectionwas administered. Amphetaminewas injected at 60min and rats were ob-
served for a further 120min.Whendistance travelledwas analysed therewas a signiﬁcant
effect of treatment [between subjects, F(5,37)=7.7, p b 0.0001,η2=0.51] aswell as a sig-
niﬁcant effect of time [within subjects, F(35, 1295) = 80.3, p b 0.0001, η2 = 0.62] and a
signiﬁcant interaction between time and treatment [F(175,1295) = 2.3, p b 0.0001]. B.
There was a signiﬁcant effect of treatment during the habituation period [F(5, 40) = 2.6,
p= 0.038, η2 = 0.34]. C. There was a signiﬁcant effect of treatment in the saline baseline
period [F(5,38) = 6.1, p= 0.0003, η2 = 0.45). D. There was a signiﬁcant effect of treat-
ment following the amphetamine injection [F(5,33) = 5.1, p = 0.0014, η2 = 0.44].
& b 0.1, ** p b 0.05, ** p b 0.01, *** p b 0.001,**** p b 0.0001.
Fig. 4. The effect of gonadectomy and testosterone replacement on amphetamine-induced locomotion. The distance traveled following amphetamine injection was greater in the
gonadectomised group compared to either group with circulating testosterone (GBV vs. SBV and GBV vs. GTV). There was no difference in distance travelled between the intact animals
and gonadectomised animals with testosterone replacement. & p b 0.1 Cohen’s d=1.1–1.3, * p b 0.05 Cohen’s d=1.2–1.4, ** p b 0.01 Cohen’s d=1.5, *** p b 0.001,**** p b 0.0001. Cohen’s
d= 1.5–1.8.
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This provides some evidence that testosterone modulation has the po-
tential to directly change dopamine neurotransmission and that chang-
es in dopamine may mediate sex hormone effects on locomotion,
although dopamine-related behaviors were not measured in our previ-
ous study and dopamine was not measured directly in the current
study. In addition, testosterone increased dopamine transporter mRNA
andprotein (Purves-Tyson et al., 2014) and inDAT knockoutmice the ab-
sence of DAT translates into a marked increase in locomotion in a novel
environment due to the lack of dopamine reuptake (Gainetdinov and
Caron, 2003), and this may contribute to why rats without circulating
testosterone in the study reported herein (and therefore we presume
less DAT) show an increase in locomotion during habituation and after
saline injection. Raloxifene treatment of gonadectomised rats also led to
a marked increase in locomotion during the saline baseline period and
this was also prevented if the rats had circulating testosterone. As such,Fig. 5. The effect of raloxifene on amphetamine-induced locomotion in rats with endogenous cir
amine injection was similar until 45minutes after injection at which point the SBR group contin
tance travelled and the difference in distance travelled reached a trend at 115minutes and statis
d= 1.5 - 1.9, *** p b 0.001 Cohen’s d= 2.2.this decrease in dopamine activity in response to a novel environment
or saline (i.e. not injection of a dopamine-potentiating drug) in animals
with testosterone presentmaybe due to a truncated time course of dopa-
mine action and this observation would be consistent with a more rapid
clearance of dopamine by DAT via increased levels of DAT.
Although these differences in locomotion were identiﬁed at base-
line, amphetamine-induced locomotion data was not normalized to sa-
line baseline data. Since we ﬁnd evidence that both the numerator
(amphetamine-induced locomotion) and the denominator (baseline lo-
comotion) may be changed by sex steroid modulation and raloxifene
treatment, thenormalization proceduremay result in skewed data rath-
er than “controlling” for individual differences in activity for each rat. As
such, that data has not been normalized and is this a potentialweakness
of our study. However, the changes in baseline locomotion may be an
important aspect of sex steroid modulation of behavior and requires
consideration when future studies are designed.culating testosterone. The distance travelled by the SBV and SBR groups following amphet-
ued to increase the distance travelledwhereas the intact group began to decrease the dis-
tical signiﬁcance at 135minutes after injection. & p b 0.1 Cohen’s d=1.2, * p b 0.05 Cohen’s
Fig. 6. The effect of raloxifene on amphetamine-induced locomotion in ratswith orwithout exogenous circulating testosterone. Raloxifene treatment signiﬁcantly increased the dopamine-
potentiating effect of amphetamine on locomotion in gonadectomised ratswith testosterone replacement (GTR) as compared to gonadectomised ratswith testosteronewithout raloxifene
(GTV).When comparingGTR vs. GTV, Cohen’s dwas 2 at 115min and 1.5 at both 120 and 145min.When p b 0.05 betweenGTR vs.GTV, Cohen’s dwas between 1.7 and 2.2 and at 125min
Cohen’s d was 2.1. When comparing GBR vs. GTR Cohen’s d was 1.6 at both 170 (p b 0.1) and 175 min (p b 0.01). & p b 0.1, * p b 0.05, ** p b 0.01, *** p b 0.001.
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Testosterone has been implicated in the modulation of dopamine
neurotransmission, although with conﬂicting evidence on the direction
of change. Some studies, all in adult male rats, indicate that testosterone
increases striatal dopamine and enhances the effect of dopamine-
potentiating drugs (de Souza Silva et al., 2009; Thiblin et al., 1999),
whilst others indicate that testosterone removal increases striatal dopa-
mine (Beatty et al., 1982; Dluzen and Ramirez, 1989; Forgie and
Stewart, 1994). Our data reported herein, althoughwe have not directly
measured dopamine release in the behaving rats, concur with the stud-
ies that indicate that testosterone removal increases striatal dopamine
activity in response to the dopamine-potentiating drug, amphetamine,
and that testosterone replacement of gondectomisedmale rats reverses
this effect. Our study differs from these previous studies as our sex ste-
roid manipulation was prior to the adolescent increase in testosterone
but our behavioural testing was in adulthood, whereas most of these
previous studies began in adulthood. Importantly our study concurs
with that of (Menniti and Baum, 1981) in which sex steroid manipula-
tion was also prior to the adolescent increase in circulating steroids
and behavioral testing in adulthood and as suchboth studies encompass
the adolescent developmental period that is well known to undergo re-
modeling of the dopamine system e.g. (Teicher et al., 1993). It is known
that peri-adolescent rodents are less sensitive to amphetamine treat-
ment than adult rodents and amphetamine produces smaller behavioral
activation in early adolescent rats compared to adult rats (Bolanos et al.,
1998; Laviola et al., 1999). Thus, our data may reﬂect an impact of tes-
tosterone on this remodeling of the dopaminergic system.
Neurotransmitter systems other than dopaminemay also contribute
to the changes in amphetamine-induced locomotion reported herein.
Amphetamine has complex acute drug effects that may also involve
norepinephrine, epinephrine, serotonin and glutamate or combinations
of these neurotransmitters. For example agonists ofmetabotropic gluta-
mate receptors 2/3 attenuate amphetamine-induced locomotion
(Pehrson andMoghaddam, 2010) and estrogen has been shown to acti-
vatemetabotropic receptor 2 signaling (Boulware et al., 2005). Agonism
of the serotonin 1A (5-HT1A) receptor and antagonism of the 5-HT2A re-
ceptor attenuates amphetamine-induced dopamine release, thus
changes in serotonin pathways can also impact amphetamine-induced
locomotion (Di Giovanni et al., 2010) and as such sex steroid modula-
tion and raloxifene treatment may modulate other neurotransmittersystems that may contribute to changes in amphetamine-induced loco-
motion and this requires investigation in future studies.
In addition, testosteronemay be inﬂuencing the locomotor response
to amphetamine via directmodulation of dopamine neurotransmission.
We have previously reported changes in gene expression of a number of
dopamine pathway-related molecules in the nigrostriatal system in re-
sponse to removal and replacement of testosterone over adolescence
(Purves-Tyson et al., 2012, 2014) that may shed light on the underlying
molecular changes induced by testosterone to contribute to this ef-
fect on amphetamine-induced locomotion. Our published molecular
data (Purves-Tyson et al., 2012, 2014) suggests that while testoster-
one may prime the midbrain neurons to make and release more do-
pamine (through increases in TH and VMAT2), it may concomitantly
also increase the ability to control the intensity and duration of dopa-
mine action by increasing re-uptake (DAT) and breakdown enzymes
that serve to terminate dopamine action (Napolitano et al., 1995;
Nirenberg et al., 1996). However, in response to amphetamine, which
reverses the direction of the dopamine transporter (i.e. results in efﬂux
of dopamine into the synaptic cleft) (Heikkila et al., 1975; Seiden et al.,
1993), it is harder to reconcile increased DAT gene expression in testos-
terone replaced rats with the overall decreased amphetamine-induced
locomotion that we report here. Indeed, DAT overexpressing mice
show increased locomotor responses to amphetamine compared to
wild type mice (Salahpour et al., 2008). However, the actions of dopa-
mine autoreceptors (DRD2 short) may also contribute to the decrease
in amphetamine-induced locomotion in testosterone-replaced rats.
Indeed, we have previously reported an increase in DRD2 pan and
DRD2 short (DRD2S) mRNA at the dopamine cell bodies (substantia
nigra) as well as in the dorsal striatum (i.e. DR mRNA in the cell bod-
ies of striatal target neurons) inmale rats (Purves-Tyson et al., 2014).
Presynaptic DRD2S autoreceptors inhibit dopamine release and
postsynaptic DRD2S receptors inhibit DRD1 responses (Rouge-Pont
et al., 2002; Usiello et al., 2000). Although we also reported an in-
crease in postsynaptic DRD2 mRNA levels, which could contribute
to increased locomotion (Lapin and Rogawski, 1995; O'Neill and
Shaw, 1999), the locomotion response reported herein indicates
that the balance of these dopamine receptor changes as a result of in-
creased testosterone levels, may contribute to a system with overall
less dopamine activity as measured by amphetamine-induced loco-
motion. In addition, themolecular changes in the dopamine pathway
may be offset or further modulated by additional changes in other
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Fig. 7. The negative relationship between amphetamine-induced locomotion and circulating testosterone level is abolished by raloxifene treatment. The total distancemovedwas divided
into 30minute time bins and Pearson’s correlations with circulating testosterone levels revealed a negative relationship between circulating testosterone level and the distance travelled
and this was lost when rats were treated daily with 5 mg/kg raloxifene.** p b 0.01, *** p b 0.001.
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motion. We propose that the cumulative effect of less DAT, less pre-
synaptic DRD2S (i.e less presynaptic autoreception) and slower
dopamine metabolism may contribute to a more gradual return to-
ward baseline locomotion levels (after amphetamine injection) in
gonadectomised rats without testosterone compared to both sham
and testosterone-replaced rats with the converse occurring in ratswith circulating testosterone. Therefore, we propose that the pres-
ence or absence of testosterone over the adolescent period and into
adulthood may modulate the response of the dopamine system to
amphetamine in adulthood and this would be consistent with the
testosterone-induced changes in dopamine pathway-related mole-
cules we and others have reported [reviewed in (Sanchez et al.,
2010)]. Studies using speciﬁc dopamine receptor antagonists and
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the components of the dopamine pathway to these changes. It is im-
portant to note that it is a limitation of this study that we have not di-
rectly measured dopamine levels in the behaving rats and this would
be necessary to conﬁrm the direct modulation of dopamine neuro-
transmission by testosterone and/or raloxifene.
It must also be considered that testosterone in the male can be
metabolized to 17β-estradiol and have effects via ERs. Testosterone
can be by metabolized to dihydrotestosterone (DHT) which acts via
AR but is further metabolized by 3α-hydroxysteroidodehyrogenase
to 3β-androstanediol which acts via ERβ (Celotti et al., 1992). 3β-
androstanediol and action of upstream steroidogenic enzymes (5α-
reductase) have been linked to sensorimotor gating deﬁcits following
dopamine activation (Devoto et al., 2012; Frau et al., 2014). This sug-
gests the possibility that raloxifene is having the opposite effect to the
estrogen-driven effects from testosterone metabolites and may there-
fore be acting as an estrogen receptor antagonist. The effects reported
here do not elucidatewhether testosterone actions are direct and/or in-
direct via it’s metabolites. However, in the study by Menniti and Baum,
1981, comparing gonadectomised (at 40 days of age) and hormone re-
placed (with silastic implants for 2–3 weeks) male rats indicated that
estradiol replacement increased amphetamine (1.5mg/kg)-induced lo-
comotion compared to gonadectomised rats and DHT or testosterone
replacement reduced amphetamine-induced locomotion (Menniti and
Baum, 1981). When the combination of DHT and estradiol was used
for replacement, DHT partially attenuated the estradiol-induced in-
crease in locomotion. This data indicates that testosterone effects on
amphetamine-induced locomotion are therefore most likely not via
ER agonism. Additional experiments using speciﬁc blockers of testoster-
one metabolism (e.g. inhibition of 5α-reductase) would be needed to
further clarify how testosterone is exerting its effects. Also, further ex-
periments using ERα and ERβ speciﬁc agonists may help to determine
which ER(s) are involved in mediating the raloxifene effects. However,
we cannot rule out that there may be complex agonist/antagonist ac-
tions at ERs when both testosterone (and it metabolites 17β-estradiol
and 3β-androstanediol) and raloxifene are present in vivo.
Raloxifene treatment of intact rats increases amphetamine-induced
locomotion
An important aspect of this study was to determine how raloxifene
modulates amphetamine-induced locomotion in the presence and ab-
sence of testosterone. Evidence suggests that estrogen can modulate
dopamine neurotransmission and amphetamine-induced locomotion
(Menniti and Baum, 1981; Sanchez et al., 2010). We sought to deter-
minewhether concomitant stimulation of ERwas able tomodulate tes-
tosterone effects on amphetamine-induced locomotion. Raloxifene, in
our study, appears to be acting in a similar manner to estrogen in the
study by Menniti and Baum (1981) and therefore, most likely as an ER
agonist. We found that ER stimulation by the SERM raloxifene appeared
to have the opposite effect on locomotor behaviour as compared to tes-
tosterone in adult male rats. Raloxifene treatment of rats with endoge-
nous testosterone potentiated amphetamine-induced hyperlocomotion
both by increasing locomotion to a higher initial level after injection
of amphetamine and by slowing the return to baseline locomotion
levels. While we found potentiation of amphetamine-induced loco-
motion by raloxifene with low to no circulating testosterone levels
(gondectomised and saline-replaced animals), we also found an
overall effect of raloxifene on circulating testosterone levels in intact
animals. This is in contrast to what has been reported in humans, that
raloxifene increases circulating testosterone inmales (Duschek et al.,
2004; Uebelhart et al., 2004), as in our experiments, raloxifene treat-
ment reduced circulating testosterone levels in intact male rats
(~40%). This difference in the effect of raloxifene on testosterone
levels between male humans and male rats may be the result of a
species difference or it may be a result of an age difference. The studiesin humans were in elderly or middle-aged men who had low endoge-
nous testosterone (Duschek et al., 2004; Uebelhart et al., 2004) and
our animals are young adults, the time of peak testosterone levels, at
the time of raloxifene administration. Thus, in sham-operated animals
the reduction in circulating testosterone by raloxifene may contribute
to the hyperlocomotion effects of raloxifene in this group (SBR). How-
ever, the activity potentiating effects of raloxifene are also found in
the testosterone-replaced animals and in gonadectomised rats with un-
detectable levels of testosterone,where in these animals raloxifene can-
not inﬂuence gonadal synthesis of circulating testosterone levels.
Thus, our results suggest that raloxifene acting independently of tes-
tosterone or acting in conjunction with decreasing testosterone
levels, can increase locomotor activity in adult male rats treated
with amphetamine. Therefore, the ultimate effect of raloxifene treat-
ment of intact male rats would be a result of the net effect of indirect
action via testosterone modulation and AR action and direct action via
ER. The loss of the negative correlation between testosterone levels
and amphetamine-induced locomotion when raloxifene is present fur-
ther supports raloxifene treatment is capable of inducing opposing ef-
fects on amphetamine-induce locomotion to testosterone.
Raloxifene has been proposed for use in men with schizophrenia as
it has been shown to ameliorate psychotic symptoms in women with
schizophrenia (Kulkarni et al., 2002; Usall et al., 2011) and improves
cognitive function in both males and females with schizophrenia
(Weickert et al., in Press). Our data raises important questions as to its
predicted clinical effect in men or whether it may have differential af-
fects on psychosis depending on the sex steroid background of the pa-
tient. In the clinic, treatment of males with raloxifene would be in the
context of endogenous circulating testosterone and thus, sex steroid/
SERM interactions need to be understood in the context of males and
their endogenous levels of testosterone. This study highlights the im-
portance of understanding the effect of raloxifene in the context of dif-
ferent genders or in people/animals with altered sex steroid receptors
(Weickert et al., 2008).
Limitations of the study
There are a number of technical aspects that require consideration
when interpreting our data. It is important to note the differences
between endogenous circulating testosterone and replaced testos-
terone that may impact the data. Endogenous testosterone levels in-
crease gradually over adolescence (between 45 days of age and
60 days of age) and also exhibit daily circadian rhythms, whereas im-
plants supply an immediate high steady state level. Although we did
not detect any differences between the GTV and SBV groups in this
study, it should be considered that these differences in testosterone
dynamics could contribute to changes in aspects such as dominance
status that may ultimately impact on neurotransmitter systems and
associated behaviors.
A further limitation of this study is that only one dose of raloxifene
(5 mg kg−1 day−1), the effects of which are typically dose-dependent,
was selected (Wu et al., 1999). Now that a raloxifene-induced effect
has been identiﬁed inmales, it will be important for future studies to ex-
amine a raloxifene dose response curve. In addition there is some evi-
dence in the literature that sex steroids can modulate the liver
parahydroxylation of amphetamine (Forgie and Stewart, 1994) and
thereby,modulate amphetamine-induced behaviors. This seems unlike-
ly to be themain or only contributor to the effects found in our study, as
we can detect direct molecular changes in brain in dopamine signaling
molecules in rats treated with similar sex steroid manipulation strate-
gies (Purves-Tyson et al., 2014).
Conclusions
This study contributes to our knowledge of how testosterone over
adolescencemay contribute to changes in the response to drugs such
83T.D. Purves-Tyson et al. / Hormones and Behavior 70 (2015) 73–84as amphetamine in adulthood and how this may be modulated by
raloxifene. It raises important considerations regarding sex steroid
based interventions for psychotic disorders involving dopaminergic
dysregulation and thus warrants further investigation. We conclude
that testosterone during adolescence attenuates locomotor re-
sponses to amphetamine in adulthood and estrogen receptor modu-
lation by raloxifene treatment in young adulthood (after adolescent
testosterone modulation), potentiates locomotor responses to am-
phetamine in adulthood.Acknowledgments
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